Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Katergi, Khaled
7  Ergebnisse:
Personensuche X
?
1

Comparative efficacy and safety of Pneumocystis jirovecii p..:

Prosty, Connor ; Katergi, Khaled ; Sorin, Mark...
Clinical Microbiology and Infection.  , 2024
Link: https://doi.org/10.1016/..
 
?
2

Risk of infectious adverse events of venetoclax therapy for..:

Prosty, Connor ; Katergi, Khaled ; Nguyen, Alex...
Blood Advances.  8 (2024)  4 - p. 857-866 , 2024
Link: https://doi.org/10.1182/..
 
?
3

Clinical Outcomes and Management of NAAT-Positive/Toxin-Neg..:

Prosty, Connor ; Hanula, Ryan ; Katergi, Khaled...
Clinical Infectious Diseases.  78 (2023)  2 - p. 430-438 , 2023
Link: https://doi.org/10.1093/..
 
?
4

2722. Risk of Infectious Adverse Events of Venetoclax Thera..:

Prosty, Connor ; Katergi, Khaled ; Nguyen, Alex...
Open Forum Infectious Diseases.  10 (2023)  Supplement_2 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
5

699. Clinical Outcomes and Management of NAAT-Positive/Toxi..:

Prosty, Connor ; Hanula, Ryan ; Katergi, Khaled...
Open Forum Infectious Diseases.  10 (2023)  Supplement_2 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
6

Identifying Modifiable System-Level Barriers to Living Dono..:

Sandal, Shaifali ; Schiller, Ian ; Dendukuri, Nandini...
Kidney International Reports.  7 (2022)  11 - p. 2410-2420 , 2022
Link: https://doi.org/10.1016/..
 
?
7

Identifying Modifiable System-Level Barriers to Living Dono..:

Sandal, Shaifali ; Schiller, Ian ; Dendukuri, Nandini...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751709/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
1-7